Ranked #2,238 of 8,699 institutional investors
MPM Bioimpact LLC
Boston, MA
$1.09B
US stock portfolio at live prices · today −$8.4M (−0.76%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $1.30B
- Change from Q2 2026
- −$340.9M (−20.79%)
- Positions
- 33 · 9 new, 9 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: put options on $48.6M. $84.5M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesCGEM 8.09%AKTS 7.27%LQDA 6.97%EWTX 5.95%TVTX 4.82%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | 9,721,081 | $88.2M | 8.09% | Reduced −0% |
| AKTS Aktis Oncology, Inc. | 4,835,872 | $79.3M | 7.27% | Unchanged |
| LQDA Liquidia Corporation | 1,342,713 | $76.0M | 6.97% | Reduced −3% |
| EWTX Edgewise Therapeutics, Inc. | 1,575,987 | $64.9M | 5.95% | Reduced −3% |
| TVTX Travere Therapeutics, Inc. | 1,088,363 | $52.6M | 4.82% | Reduced −3% |
| DYN Dyne Therapeutics, Inc. | 3,208,146 | $51.4M | 4.72% | Added +67% |
| TRVI Trevi Therapeutics, Inc. | 2,978,906 | $40.9M | 3.75% | Reduced −3% |
| RLAY Relay Therapeutics, Inc. | 2,369,578 | $37.7M | 3.46% | Reduced −2% |
| IMCR Immunocore Holdings plc | 1,203,289 | $32.0M | 2.94% | New |
| ORKA Oruka Therapeutics, Inc. | 300,000 | $29.3M | 2.68% | New |
| PVLA Palvella Therapeutics, Inc. | 197,633 | $28.8M | 2.64% | Reduced −3% |
| DBVT DBV Technologies S.A. | 3,044,659 | $28.7M | 2.63% | Reduced −17% |
| CORT Corcept Therapeutics Incorporated | 422,000 | $27.4M | 2.51% | Reduced −45% |
| TARS Tarsus Pharmaceuticals, Inc. | 352,676 | $27.4M | 2.51% | Added +10% |
| TSHA Taysha Gene Therapies, Inc. | 7,262,959 | $27.4M | 2.51% | Added +61% |
| ABVX ABIVAX Société Anonyme | 328,379 | $26.5M | 2.43% | Reduced −2% |
| VSTM Verastem, Inc. | 3,851,604 | $26.4M | 2.42% | New |
| NTRA Natera, Inc. | 90,585 | $26.3M | 2.41% | Reduced −2% |
| VIR Vir Biotechnology, Inc. | 2,809,711 | $24.9M | 2.29% | New |
| STOK Stoke Therapeutics, Inc. | 925,133 | $24.9M | 2.28% | Added +28% |
| ODTX Odyssey Therapeutics, Inc. | 1,289,091 | $23.6M | 2.17% | New |
| IOVA Iovance Biotherapeutics, Inc. | 2,835,734 | $20.7M | 1.90% | New |
| BLTE Belite Bio, Inc | 133,387 | $20.1M | 1.85% | Reduced −3% |
| ACRS Aclaris Therapeutics, Inc. | 5,178,127 | $18.1M | 1.66% | Added +397% |
| ANL Adlai Nortye Group Ltd. | 1,956,618 | $17.7M | 1.63% | Added +1% |
| NGNE Neurogene Inc. | 771,839 | $17.7M | 1.62% | New |
| ANNX Annexon, Inc. | 4,290,616 | $14.6M | 1.34% | Added +21% |
| ORIC ORIC Pharmaceuticals, Inc. | 1,821,951 | $14.0M | 1.29% | Reduced −3% |
| TRAX First Tracks Biotherapeutics, Inc. | 254,374 | $11.3M | 1.04% | New |
| GLUE Monte Rosa Therapeutics, Inc. | 1,125,216 | $10.0M | 0.92% | Reduced −3% |
| BIOA BioAge Labs, Inc. | 1,856,748 | $8.7M | 0.80% | Added +11% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 1,667,272 | $4.1M | 0.37% | New |
| DRUG Bright Minds Biosciences Inc. | 195,669 | $4.1M | 0.37% | Reduced −3% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| RVMD Revolution Medicines, Inc. | 492,483 | $78.5M |
| DNTH Dianthus Therapeutics, Inc. | 420,002 | $35.6M |
| RARE Ultragenyx Pharmaceutical Inc. | 1,418,215 | $24.4M |
| MLTX MoonLake Immunotherapeutics | 1,606,967 | $17.7M |
| SNDX Syndax Pharmaceuticals, Inc. | 1,333,523 | $12.2M |
| ALMS Alumis Inc. | 2,019,020 | $8.7M |
| TRDA Entrada Therapeutics, Inc. | 1,253,053 | $5.8M |
| CNTX Context Therapeutics Inc. | 1,299,046 | $219K |
| HOWL Werewolf Therapeutics, Inc. | 80,142 | $79K |